Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Official title: Transcriptomics, pathobiology, and cardiac event in hypertrophic cardiomyopathy
Funded at Columbia University Health Sciences · NIH-11395391 · Data updated 2026-11-12
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $686,813 |
| NIH project number | 5R01HL168382-04 |
| Project ID | NIH-11395391 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with hypertrophic cardiomyopathy enrolled in the HCM2 biorepository who have available biopsy or plasma samples and follow-up data.
✕Less likely to help
Patients not enrolled in the HCM2 biorepository or without available tissue/blood samples may not benefit directly.
What this research studies
This project uses data and samples from a large group of people with hypertrophic cardiomyopathy collected over years to look at gene activity in heart tissue and blood. By profiling transcripts in both myocardium and plasma, the study aims to link molecular pathways with disease status and risk of major events like arrhythmias or heart failure. The findings could help identify which patients are at higher risk and may benefit most from preventive strategies.
Why it matters
Potential benefit: If successful, the research could lead to better ways to predict who is at risk for major heart events and tailor preventive treatments for hypertrophic cardiomyopathy.
How similar studies have gone: Previous biorepository efforts have produced rich data; this study adds transcriptomic profiling to link molecular signals with outcomes.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Shimada, Yuichi — Columbia University Health Sciences
- Study coordinator: Shimada, Yuichi
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
-
Boosting heart cell energy in hypertrophic cardiomyopathy
New approaches to improve mitochondrial energy in heart cells for people with hypertrophic cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.